title: [Therapy of multiple myeloma and its complications].
abstract: A dramatic improvement in the prognosis of multiple myeloma has been obtained since treatment with alkylating agents was introduced in the sixties. In recent years much effort has been made to ameliorate the obtained results by employing polychemotherapy schedules of treatment. However, no significant improvements with respect to the conventional melphalan-prednisone treatment, in terms of survival duration, have been observed. New therapeutic approaches, such as the use of biological response modifiers and the autologous or allogeneic bone marrow transplantation offer new perspectives for multiple myeloma patients. In this paper we discuss current trends in the therapy of multiple myeloma and of related complications.
authors.affiliation: Ematologia, Dipartimento di Biopatologia umana, Università La Sapienza, Roma.
authors.forename: G
authors.initials: G
authors.lastname: Avvisati
authors.forename: A
authors.initials: A
authors.lastname: Pulsoni
authors.forename: M T
authors.initials: MT
authors.lastname: Petrucci
authors.forename: M
authors.initials: M
authors.lastname: Tribalto
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000628:therapy; D000477:Alkylating Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology; D007370:Interferon Type I / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence
chemical_list: D000477:Alkylating Agents; D007370:Interferon Type I; D008558:Melphalan; D011241:Prednisone
vernacular_title: Terapia del mieloma multiplo e delle sue complicanze.